Stay updated with breaking news from Liminal Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LAVAL, QC and CAMBRIDGE, England, June 5, 2023 /PRNewswire/ - Liminal BioSciences Inc. announced the voting results from its Annual General Meeting of Shareholders held virtually on June 5, 2023.... | June 5, 2023
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of...
/PRNewswire/ -- Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting...
LMNL6326 nominated as lead preclinical candidate for OXER1 antagonist development program, targeting the treatment of eosinophil-driven diseasesAdvancement of clinical trial application (CTA)
GPR84 antagonist program and OXER1 antagonist program on track to meet previously stated milestones in 2023Closed March 31, 2023 with just over CAD26.9 million cash on hand, expecting to provide